To dose or not to dose: that is the (starch) question ... by Kaplan, Lewis J
Hydroxyethyl starch (HES) has been viliﬁ  ed, praised, or 
largely ignored as a resuscitation ﬂ  uid depending on the 
setting within which the HES is administered. Th  e  most 
recent HES focus has been on renal injury when HES is 
administered to patients with severe sepsis or septic 
shock. Boussekey and colleagues have provided us with a 
single-center, 2-year view of how HES use in the intensive 
care unit relates to renal function [1]. Several elements of 
this study merit discussion.
First, Boussekey and colleagues’ study is similar to 
another that provided a snapshot view of ﬂ  uid resusci-
tation in a host of European intensive care units [2]. Most 
notably, HES use was not associated with renal injury 
even when administered to patients with sepsis. Th  is 
ﬁ  nding reﬂ  ects a relatively low dose of HES, consistent 
with that used in the current study – quite diﬀ  erent from 
the doses used in studies decrying the use of HES [3-5].
Like the study of Sakr and colleagues [2], HES was only 
one component of a multimodal approach to ﬂ  uid 
manage ment.  Th   is critical element underscores the 
obser  vation that HES does not provide signiﬁ  cant free 
water. Resuscitation with only HES (as predominantly 
occurs in HES trials) will therefore establish a hyper-
oncotic state and predictably lead to acute kidney injury 
(AKI) or acute renal failure (ARF) [6].
Th   ird, the authors are to be congratulated on applying 
an objective and evidence-based approach to categorizing 
renally relevant events – the RIFLE criteria [7]. Most 
trials evaluating renal dysfunction are binary, in that ARF 
is present or absent; AKI is often not addressed. More-
over, the deﬁ  nitions used in non-RIFLE trials are often 
based on a percentage change in creatinine (100%), a 
creatinine threshold (>2.0 mg%), and the need for dialysis 
regardless of modality without specifying the triggering 
criteria. Worse still, the HES and diluents used are vastly 
diﬀ  erent between trials.
Boussekey and colleagues used a modern low 
molecular weight and degree of substitution starch, and 
the diluent was not speciﬁ  ed but presumed to be 0.9% 
normal saline solution. Unfortunately, they did not report 
on the presence of hyperchloremic metabolic acidosis 
during their trial, a condition that is associated with 
reduced renal blood ﬂ   ow and reduced glomerular 
ﬁ  ltration rate. Patients in the study were divided into two 
groups based on whether HES was or was not adminis-
tered at any time. Despite having administered HES to a 
more ill patient population with more shock (septic in 
particular), more vasopressor use, and more surgery and 
anesthesia exposure, the incidence of AKI or ARF was no 
diﬀ  erent between the two groups. Th   is is a key message 
for those who, at least, use the same HES.
It is likely that the authors’ ﬁ  ndings are applicable to 
other groups, as Sakr and colleagues’ study used a diﬀ  er-
ent HES to that used in this trial. Moreover, it would be 
appropriate to use the data from this trial as another 
impetus to re-examine our assumptions about HES in 
diﬀ  erent settings. Much of the thoughts around HES and 
AKI or ARF stem from renal biopsy in those patients 
with ARF after having received HES. We do not, however, 
biopsy those patients without AKI/ARF who have 
received HES. We thus do not know the likelihood of 
having HES deposition and persistence in renal tubules 
in the absence of AKI/ARF. Furthermore, in the phase III 
US Food and Drug Administration registration trial of a 
large molecular weight and high degree of substitution 
starch in the US, much larger doses than used in the 
present trial (upwards of 5,000 cc) were not associated 
with any renal dys  function [8]. One must wonder 
whether the data cited to establish a HES moratorium are 
conditionally speciﬁ   c to sepsis, to an artifact of 
hyperoncoticity, to an eﬀ  ect of the starch diluent, or to 
some combination.
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crystalloids or colloids promote, abrogate, or ameliorate 
AKI in the critically ill or injured patient has been 
recently published [9]. Boussekey and colleagues have 
taken us another step down the path of understanding 
how colloids appropriately ﬁ   t into the intensivists’ 
armamentarium. Further research will be required to 
discern whether the excellent results the authors have 
obtained derive directly from the biophysical and 
biochemical properties of the starch itself, from the 
patient populations in which the HES is used, or from 
other factors such as the acid–base milieu into which the 
starch is placed. One element is clear from this 
manuscript – that the use of the RIFLE criteria allows 
one to employ an objective means to evaluate the impact 
of a particular therapy on renal function. Perhaps all 
manuscripts evaluating renal function should follow 
these authors’ lead so that we may truly learn whether or 
not to dose.
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